




A PATH TO PREVENTION:

State Profile: Tennessee

On-time HPV vaccination protects best. HPV vaccination is routinely recommended at **age 11 or 12 years and may be started at age 9**. HPV vaccination is recommended for everyone ages 9-26. It's not too late to catch up on HPV vaccination. People ages 27-45 are also strongly encouraged to talk with a health care provider to see if HPV vaccination is right for them.


HPV VACCINATION RATES FOR 13-17 YEAR-OLDS AS OF 2023:



Tennessee has increased HPV vaccination coverage of **≥1 dose by 22% and up to date (UTD) by 19% since 2016**. However, coverage remains **lower than the U.S. average** and below the Healthy People 2030 goal of 80% UTD. Compared to meningitis and whooping cough (Tdap) vaccines routinely recommended for adolescents, HPV vaccination coverage lags. Tennessee vaccination rates **among 13-17-year-olds were 86% for meningitis vaccine and 93% for Tdap vaccine in 2023**.




HPV vaccination protects against more than 90% of HPV cancers.




HPV VACCINATION RATES FOR 13-17 YEAR-OLDS AS OF 2022:


HPV Vaccination by Race/Ethnicity




HPV Vaccination by Insurance Coverage



HPV Vaccination by Urbanicity



HPV Vaccination by Sex



----- Healthy People 2030 ■ ≥1 HPV Vaccination ■ HPV Vaccination Up-to-date

HPV vaccination data sources: CDC NIS-TEEN, 2023 accessed in TeenVax View, 2024

Demographic data for 2018-2022 are the most recently available.

HPV CANCERS:

HPV is a common virus linked to six types of cancer. The two most common HPV-associated cancers are oropharyngeal and cervical cancers. **Incidence rates of HPV cancers overall and oropharyngeal cancer are higher in Tennessee than the U.S. averages. Incidence rates of cervical cancer are lower in Tennessee compared to the U.S. averages.**

New Cases

	All HPV Cancers	Oropharyngeal Cancer	Cervical Cancer
United States Overall	12.5	5.2	7.1
Tennessee Overall	13.2	5.7	6.6
United States	Male: 11.2, Female: 13.9	Male: 9.1, Female: 1.6	Tennessee ranks in the Top 30 nationally in cervical cancer incidence rates.
Tennessee	Male: 11.9, Female: 14.5	Male: 10.0, Female: 1.9	

Incidence rates shown are cases per 100,000 persons.

ACTION STEPS:

Identify and engage key partners in HPV vaccination to develop, implement, and evaluate priority evidence-based interventions to increase HPV vaccination coverage in clinical, community and policy settings in Tennessee:

- Encourage starting HPV vaccination at age 9 to increase series completion by age 13.
- Expand HPV vaccination training, education, and motivational interviewing opportunities for healthcare providers, including pediatricians, primary care physicians, gynecologists, dentists, pharmacists, and advanced practice providers, to support strong provider recommendations and combat parental hesitancy.
- Implement health system changes, such as client reminders, EHR prompts, and provider assessment and feedback, to increase HPV vaccination.
- Explore innovative approaches to reach key populations, including mobile HPV vaccination clinics, communication campaigns to improve public awareness, and targeted efforts to address disparities in rural areas.
- Identify strategies to improve HPV vaccination coverage for adolescents living in rural areas.
- Engage and support state-level partners in the development and implementation of strategic plans for the elimination of HPV cancers, beginning with cervical cancer, as a public health concern.
- Explore opportunities to implement school-based strategies to improve HPV vaccination coverage.

Pingali C, Yankey D, Chen M, et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years – National Immunization Survey-Teen, United States, 2023. *MMWR Morb Mortal Wkly Rep* 2024;73:708–714. DOI: <http://dx.doi.org/10.15585/mmwr.mm7333a1>

U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; <https://www.cdc.gov/cancer/dataviz>, released in June 2024.